Breaking News, Financial News

Financial Report: Hospira 2Q

Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex.

Hospira 2Q

2Q Revenues: $968.2 million (+1%)

2Q Earnings: $83.5 million (+227%)

YTD Revenues: $2.0 billion (+9%)

YTD Earnings: $225.2 million (+18%)

Comments: Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex. Other global Pharma revenues were $149.6 million (-16%). YTD Specialty Injectables sales were $1.2 billion (+29%). Other Pharma revenues were $295.7 million (-15%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters